KalVista Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
KalVista Pharmaceuticals has a total shareholder equity of $88.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $114.0M and $25.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$75.59m |
| Equity | US$88.58m |
| Total liabilities | US$25.39m |
| Total assets | US$113.97m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 4XC1's short term assets ($104.1M) exceed its short term liabilities ($19.1M).
Long Term Liabilities: 4XC1's short term assets ($104.1M) exceed its long term liabilities ($6.3M).
Debt to Equity History and Analysis
Debt Level: 4XC1 is debt free.
Reducing Debt: 4XC1 has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4XC1 has sufficient cash runway for 9 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: 4XC1 is forecast to have sufficient cash runway for 7 months based on free cash flow estimates, but has since raised additional capital.